Key Insights

Highlights

Success Rate

100% trial completion (above average)

Treatment Research

1 treatments under study, led by Anterion

Related Conditions

Often studied with 9 related conditions

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 50/100

Termination Rate

0.0%

0 terminated out of 2 trials

Success Rate

100.0%

+13.4% vs benchmark

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 1 completed with results

Key Signals

100% success

Data Visualizations

Phase Distribution

Trial Status

Not Yet Recruiting1
Completed1

Trial Success Rate

100.0%

Benchmark: 86.6%

Based on 1 completed trials

Clinical Trials (2)

Showing 2 of 2 trials
NCT07694817Not Yet Recruiting

Clinical Predictors of Visual Outcome in Patients Affected With Ocular Surface Diseases

NCT04130490Completed

The Heidelberg Engineering ANTERION Anterior Segment Cornea and IOL Precision and Agreement Study

Showing all 2 trials

Research Network

Common Treatments

  • Anterion1

Active Sponsors

  • IRCCS San Raffaele1
  • Heidelberg Engineering GmbH1

Top Investigators

  • Mitchell Dul1

    State University of New York College of Optometry

Related Conditions

  • Cataract1
  • Cornea Inflamed1
  • Iol1
  • Neurotrophic Keratopathy1
  • Cornea Disease1

Activity Timeline